Estrella Immunopharma Insider Trades
NASDAQ: ESLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Estrella Immunopharma insider activity
Over the last 12 months, Estrella Immunopharma insiders reported 2 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Liu Cheng (CEO) reporting a transaction in 100,000 shares at $0.815 on Aug 25, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ESLA's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
ESLA insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 25, 2026 | Liu ChengCEO | Option exercise | 100,000 | $81.50K | Form 4 |
| Aug 18, 2026 | Xu JiandongChief Financial Officer | Option exercise | 100,000 | $81.50K | Form 4 |
| Oct 7, 2025 | Xu JiandongChief Financial Officer | Buy | 1,000 | $1.33K | Form 4 |
| Sep 22, 2025 | Xu JiandongChief Financial Officer | Buy | 1,000 | $1.16K | Form 4 |
| Sep 11, 2025 | Xu JiandongChief Financial Officer | Buy | 100 | $104 | Form 4 |
| Sep 29, 2023 | Owl Creek Asset Management, L.P. & ALTMAN JEFFREY A10% Owner | other | 255,000 | $2.77M | Form 4 |
| Mar 4, 2022 | Li JianweiCo-Chief Executive Officer | Buy | 141,970 | $44.68B | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4